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Edited by Varda RotterAbstract The p53 protein is one of the best-known tumour sup-
pressors. Recently discovered ASPP1 and ASPP2 are speciﬁc
activators of p53. To understand, if apoptosis-stimulating pro-
tein of p53 (ASPP) inactivation oﬀers a selective advantage to
tumors that have wild-type p53, we measured the mRNA expres-
sion of ASPP1 and ASPP2 in tumor cell lines retaining wide-
type p53. In addition, the CpG island methylation status of
ASPP1 gene and ASPP2 gene in the 5 0-untranslated region
was also investigated in order to understand the possible cause
of abnormal expression of ASPP1 and ASPP2 in the tumor cell
lines retaining wide-type p53. The data showed that mRNA
expression of ASPP1 and ASPP2 is downregulated and CpG is-
land tested is hypermethylated. These results indicated that
ASPP CpG island aberrant methylation could be one molecular
and genetic alteration in wild-type p53 tumours.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The p53 protein is one of the best-known tumour suppres-
sors. The p53 gene is also one of the most frequently mu-
tated genes [1]. Mutations in p53 gene have been found in
about 50% of human cancers [2,3]. The other 50% of human
tumours retain wild-type p53. Why wild-type p53 is unable
to perform its duty as a tumour suppressor in these tu-
mours? This question remains unclear. Recently, a new fam-
ily of protein, apoptosis-stimulating protein of p53 (ASPP)
was discovered [4,5]. This discovery may suggest some new
answers to this question. The ASPP family consists of three
members: ASPP1, ASPP2, and inhibitory member of theAbbreviations: ASPP, apoptosis-stimulating protein of p53; iASPP,
inhibitory member of the ASPP family; MSP, methylation-speciﬁc
PCR; RT-PCR, reverse transcription PCR
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doi:10.1016/j.febslet.2005.01.069ASPP family (iASPP). ASPP1 and ASPP2 act as potent acti-
vators of p53. iASPP acts as an inhibitor of p53. The apop-
totic function of p53 is stimulated by ASPP1 and ASPP2
and inhibited by iASPP [6–8].
To understand, if ASPP inactivation oﬀers a selective advan-
tage to tumours that have wild-type p53, we measured the
mRNA expression of three p53 wild-type cancer cell lines,
HEPG-2, MCF-7, and A549. We also detected the CpG island
methylation status of ASPP1 gene and ASPP2 gene in the 5 0-
untranslated region in order to understand the possible cause
of abnormal expression of ASPP1 and ASPP2 in three cancer
cell lines.2. Materials and methods
2.1. Cell lines
The human cancer cell lines used in this study were HEPG-2,
MCF-7, and A549, obtained from the Southwest Hospital (Chong-
qing, PRC). The normal control used was ﬁbroblast cell. All cell
lines were grown in Dulbecco modiﬁed Eagle medium supplement
with 10% fetal calf serum, 100 U/ml benzylpenicillin, and 100 U/
ml streptomycin sulfate in a humidiﬁed atmosphere containing 5%
of CO2 at 37 C.
2.2. DNA and RNA preparation
Total DNA and RNA were extracted from various cancer cell
lines and ﬁbroblast cell using Tirpure-Isolation-Reagent (Roche,
USA).
2.3. RNA expression level determination by RT-PCR
Reverse transcription PCR (RT-PCR) kits (TaKaRa, Japan) were
used to synthesize cDNA from 2 lg of total RNA using random
hexamer primers. cDNA synthesis was carried out, as suggested by
the kit protocol, using AMV reverse transcriptase. The reverse tran-
scription was carried out for 45 min at 48 C. An incubation at
99 C for 5 min was carried out to inactivate the reverse transcriptase.
5 ll of cDNA was used to amplify the target regions of ASPP1 or
ASPP2. b-Actin cDNA fragments were also ampliﬁed as a positive
control. The RT-PCR primers of ASPP1 and ASPP2 are designed
using Primer Premier 5.0 software. The nucleotide sequences of these
primers and their PCR conditions are summarized in Table 1. After
PCR, 8 ll of product was mixed with 1 ll of 10· loading dye and then
run on 1.5% agarose gel. Electrophoresis was carried out at 100 V at
ambient temperature. The bands on the gels were visualized by ethi-
dium bromide staining. Electrophoresis proﬁles were analyzed by the
software, Gel-Pro3.1 (Media Cybernetics Inc., USA). The ratio of
the integrated optical density (IOD) of ASPP and b-actin represented
the mRNA level. The PCR products of ASPP1 and ASPP2 were 498
and 391 bp, respectively.blished by Elsevier B.V. All rights reserved.
Fig. 1. Design of MSP primers for ASPP1 and ASPP2. (A) Original sequence before bisulﬁte treatment.CpG dinucleotides are underlined. (B)
Unmethylated sequence after bisulﬁte treatment. All cytosines were deaminated and converted to thymine. Unmethylated primers are double
underlined. (C) Methylated sequence after bisulﬁte treatment. All cytosine residues at CpG sites remained unchanged although other cytosines were
converted to thymine. Methylation primers are double underlined. The GenBank Accession Numbers for the ASPP1 and ASPP2 nucleotide
sequences in this ﬁgure are AJ318887 and AJ318888, respectively. Shading indicates the ATG transitional initiation codon.
Table 1
Summary of the primer sets and PCR conditions for ASPP1 and ASPP2
Primer Sequence Pre-PCR incubation Denature Annealing Extension Cycle Final
incubation
RT-PCR
ASPP1-f 50-GCAGCACACAGCGCCTTAAATAAG-30 95 C, 3 min 94 C, 30 s 56 C, 30 s 72 C, 45 s 30 72 C, 8 min
ASPP1-r 50-TCCATTGTCCACATCGGCCAAGGT-30
ASPP2-f 50-TATCTAATCCTTACCGAAACC-30 95 C, 3 min 94 C, 30 s 55 C, 30 s 72 C, 45 s 30 72 C, 8 min
ASPP2-r 50-CCCTCAGGCTCATAATCAA-3 0
Methylation
ASPP1-Uf 50-TTTTGTATTTTGTTGTAGTTGTTGTT-3 0 94 C, 5 min 94 C, 30 s 51 C, 30 s 72 C, 30 s 40 72 C, 8 min
ASPP1-Ur 50-CACAAAAAAAATCCACAACACCC-30
ASPP1-Mf 50-CGTATTTCGTCGTAGTTGTCGTT-30 94 C, 5 min 94 C, 30 s 51 C, 30 s 72 C, 30 s 40 72 C, 8 min
ASPP1-Mr 50-CGAAAAAAATCCGCGACGCCC-30
ASPP2-Uf 50-GGTGTTTTAGTTTGTGTGGAGG-30 94 C, 5 min 94 C, 30 s 51 C, 30 s 72 C, 30 s 40 72 C, 8 min
ASPP2-Ur 50-CAAACTAAAATACCCCAAAAAATCA-30
ASPP2-Mf 50-GTGTTTTAGTTCGCGCGGAGG-30 94 C, 5 min 94 C, 30 s 50.5 C, 30 s 72 C, 30 s 40 72 C, 8 min
ASPP2-Mr 50-ACCGAACTAAAATACCCCGAAAA-3
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DNA bisulﬁte treatment was carried out using the reagents provided
in the CpGenome DNA Modiﬁcation Kit (Intergen, Purchase, NY,
USA). Brieﬂy, 1 lg of DNA was denatured using NaOH and treated
with sodium bisulﬁte for 18 h. Modiﬁed DNA was resuspended in
30 ll of TE (10 mM Tris/0.1 mM EDTA, pH 7.5) and stored immedi-
ately at 20 C [9,10].
2.5. Methylation-speciﬁc PCR analysis conditions
PCR was performed using Taq polymerase (Promega) and the hot
start procedure. The ASPP-speciﬁc primer sets are designed to locate
on the 5 0-untranslated region of ASPP gene using MethPrimer soft-
ware ([11,12], Fig. 1). Primer set U will anneal to unmethylated
DNA that has undergone a chemical modiﬁcation. Primer set M will
anneal to methylated DNA that has undergone a chemical modiﬁca-
tion. The unmethylated sequence of the ASPP gene was detected
with ASPP-Uf and ASPP-Ur. The methylated sequence of ASPP
gene was detected with ASPP-Mf and ASPP-Mr (Table 1). The
PCR mixture (50 ll) contained 2.0 mM MgCl2, 0.2 mM each of 4
dNTPs, 1.0 mM each of oligonucleotide primers, and 5 units of
Taq DNA polymerase. PCR conditions are listed in Table 1. After
PCR, 9 ll PCR product was mixed with 1.5ll of 10· loading dye
and then run on 2% agarose gel. Electrophoresis was carried out
at 100 V at ambient temperature. The bands on the gels were visu-
alized by ethidium bromide staining.Fig. 2. mRNA expression of ASPP-1 in tumor cell lines (HEPG-2,
MCF-7 and A549) and normal control (Fibroblast). (A) Agarose gel
electrophoresis of RT-PCR ampliﬁed products; (B) relative content of
ASPP-1 mRNA. The ratio of the integrated optical density (IOD) of
ASPP-1 and b-actin represented the relative mRNA level.
Fig. 3. mRNA expression of ASPP-2 in tumor cell lines (HEPG-2,
MCF-7 and A549) and normal control (Fibroblast). (A) Agarose gel
electrophoresis of RT-PCR ampliﬁed products. (B) Relative content of
ASPP-2 mRNA. The ratio of the integrated optical density (IOD) of
ASPP-2 and b-actin represented the relative mRNA level.3. Results and discussion
Recently, the ASPP family was identiﬁed as potent activa-
tors of p53 [4]. The apoptotic function of p53 is stimulated
by two members of the ASPP family, ASPP1 and ASPP2.
Binding to the DNA binding domains of p53, ASPP1 and
ASPP2 speciﬁcally stimulates the transactivation function of
p53 on promoters of proapoptotic genes [4]. Therefore, the
ASPP proteins appeared to be acting to speciﬁcally enhance
the ability of p53 to cause apoptosis.
Human tumours can be divided into two kinds. One is tu-
mours with wide-type p53. The other is tumours with mu-
tated p53. In tumours, where p53 has been mutated, p53 is
no longer able to interact with the ASPP proteins, then a cell
which would otherwise have died is now able to survive,
allowing the mutation to persist [13]. In addition, in tumours
where p53 has not been mutated, a selective advantage may
have occurred as a consequence of the downregulation of
ASPP1 and ASPP2, which would then prevent p53 from
causing cell death [13]. Our study in three tumour cell lines
with wide-type p53 shows that the mRNA expression of
ASPP1 and ASPP2 is lower than that of ASPP in the normal
control (Figs. 2 and 3). These results, together with the re-
search of Lu and coworkers [4] in breast cancer, suggest that
the downregulation ASPP may be one of characters in tu-
mours with wild-type p53. Lu and coworkers used semiquan-
titative RT-PCR technique to study the expression levels of
both ASPP1 and ASPP2 in a panel of paired normal and tu-
mor RNA samples derived from 58 breast cancer patients.
Forty of these breast carcinomas express wild-type p53 while
the other 18 express mutant p53. The results showed that
among the 40 carcinoma samples with wild-type p53, reduced
expression levels of ASPP1 and ASPP2 were detected in 24
(60%) and 9 (22.5%) samples, respectively. Among the 18 mu-
tant p53-expressing tumor samples, only three and two tu-
mors, respectively, showed reduced levels of expression of
ASPP1 and ASPP2 (16% and 11%, respectively) [4]. The
number of tumors having reduced expression of ASPP that
are wild-type for p53 is much higher than that with mutantp53. As the expression levels of ASPP1 and ASPP2 were
compared between normal cells and carcinomas derived from
the same individuals, they conclude that there is a selective
Fig. 4. Methylation status of ASPP1 (A) and ASPP2 (B) in cancer cell
lines and normal ﬁbroblast cell. 1–2, HEPG-2; 3–4, MCF-7; 5–6, A549;
7–12, ﬁbroblast cell. M band, methylation band; U band, unmethy-
lation band; M, methylation primer sets ampliﬁed products; U,
unmethylation primer sets ampliﬁed products; L, DNA Marker.
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and ASPP2 [4].
What is the cause of ASPP downregulation in tumours
retaining wild-type p53? Some of the possible reasons may
be gene mutation or epigenetic modiﬁcation. But, up to now,
ASPP gene mutation has not been found [13]. Whether the
ASPP gene themselves are subject to mutation during tumouri-
genesis remains to be seen. However, our study here shows
that epigenetic modiﬁcation may happen to ASPP gene in tu-
mour cell lines retaining wild-type p53. We observed that
ASPP1 and ASPP2 gene CpG islands in the 5 0-untranslated re-
gion were hypermethylated in three tumor cell lines retaining
p53 wild-type and were unmethylated in normal ﬁbroblast cell
(Fig. 4). These results indicated that the changes of CpG island
methylation status of ASPP1 and ASPP2 gene might be an
important factor in tumors that possess wild-type p53. Because
upstream regulators of ASPP have not yet been identiﬁed,
more work is needed to clear the precise mechanism of altered
ASPP1 and ASPP2 expression in tumors. The identiﬁcation of
ASPPs promoter region and study of its methylation status are
currently under investigation.
DNA methylation is the main epigenetic modiﬁcation in hu-
mans [14], and changes in methylation patterns play an impor-
tant role in tumorigenesis. Hypermethylation of normally
unmethylated CpG islands in the promoter regions often oc-
curs in important tumor suppressor genes such as VHL,
hMLH1 and p16 [15–17]. Our study here shows that hyperme-thylation is also happened in the 5 0-untranslated region of
ASPP1 and ASPP2 gene. This observation suggested that
ASPP downregulated expression in tumour cells retaining
wild-type p53 might be relative to the abnormal methylation
status of ASPP gene. Therefore, the ASPP aberrant methyla-
tion could be one molecular and genetic alteration in tumours
retaining wild-type p53.
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